Recent Updates
Recently added Catalysts
WVE Positive Sentiment Score: 70/100

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

Key Takeaway: Wave Life Sciences Ltd. will host a live webcast and conference call on July 30, 2026, to discuss its second quarter financial results and provide business updates. The event will be accessible via the company's investor relations website. Wave focuses on RNA medicines and has a diverse pipeline addressing multiple health conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is advancing RNA medicines with innovative technologies.
  • The company is set to provide key financial updates and business insights.
  • Wave's pipeline includes promising programs for various diseases.

Full Press Release Details

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company’s second quarter 2026 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website:https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing linkhere.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visitwww.wavelifesciences.comand follow Wave onXandLinkedIn.

Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827

Investors:James SaliernoDirector, Investor Relations+1 617-949-4043InvestorRelations@wavelifesci.com

Media:Katie SullivanSenior Director, Corporate Communications+1 617-949-2936MediaRelations@wavelifesci.com

Frequently Asked Questions

When will Wave Life Sciences announce its Q2 2026 results?

Wave Life Sciences will announce its Q2 2026 results on July 30, 2026.

How can I access the Wave Life Sciences conference call?

The conference call can be accessed via the audio-conferencing link provided on their website.

What is the focus of Wave Life Sciences?

Wave Life Sciences focuses on RNA medicines to transform human health.

Where is Wave Life Sciences headquartered?

Wave Life Sciences is headquartered in Cambridge, Massachusetts.

Last updated: Jul 23, 2026